KHB(SZ:002022) Sou Hu Cai Jing·2026-01-30 13:56Group 1 - The company Kewah Bio expects a net loss attributable to shareholders of 580 million to 740 million yuan for 2025, with basic earnings per share loss estimated at 1.1276 to 1.4387 yuan [1] - In the same period last year, the company reported a net loss of approximately 641 million yuan, with a basic earnings per share loss of 1.2687 yuan [1] - The primary reason for the performance change is significant adverse impact from asset impairment provisions, which the company plans to assess and test comprehensively based on industry trends and actual operating conditions [1] Group 2 - The IVD industry is facing intensified competition due to policy changes and market pressures, leading to a decline in both revenue scale and product gross margins year-on-year [1] - Factors such as medical procurement policies, DRG payment reform, mutual recognition of test results, adjustments in testing service fees, and unbundling of testing packages are reshaping the competitive landscape of the industry [1] - The demand for certain routine testing projects is contracting, coupled with downward pressure on product prices, which directly affects the company's profitability [1]